Literature DB >> 17441925

Immunotherapy for metastatic renal cell carcinoma.

David F McDermott1, Brian I Rini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17441925     DOI： 10.1111/j.1464-410X.2007.06818.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  8 in total

Review 1.  Circulating biomarkers in advanced renal cell carcinoma: clinical applications.

Authors:  Maria Hernandez-Yanez; John V Heymach; Amado J Zurita
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

2.  Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients.

Authors:  Chiara Grisanzio; Apryle Seeley; Michelle Chang; Michael Collins; Arianna Di Napoli; Su-Chun Cheng; Andrew Percy; Rameen Beroukhim; Sabina Signoretti
Journal:  J Pathol       Date:  2011-06-27       Impact factor: 7.996

Review 3.  Treatment selection in metastatic renal cell carcinoma: expert consensus.

Authors:  Bernard Escudier; Cezary Szczylik; Camillo Porta; Martin Gore
Journal:  Nat Rev Clin Oncol       Date:  2012-04-10       Impact factor: 66.675

Review 4.  State of the science: an update on renal cell carcinoma.

Authors:  Eric Jonasch; P Andrew Futreal; Ian J Davis; Sean T Bailey; William Y Kim; James Brugarolas; Amato J Giaccia; Ghada Kurban; Armin Pause; Judith Frydman; Amado J Zurita; Brian I Rini; Pam Sharma; Michael B Atkins; Cheryl L Walker; W Kimryn Rathmell
Journal:  Mol Cancer Res       Date:  2012-05-25       Impact factor: 5.852

5.  Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney.

Authors:  Rameen Beroukhim; Jean-Philippe Brunet; Arianna Di Napoli; Kirsten D Mertz; Apryle Seeley; Maira M Pires; David Linhart; Robert A Worrell; Holger Moch; Mark A Rubin; William R Sellers; Matthew Meyerson; W Marston Linehan; William G Kaelin; Sabina Signoretti
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

6.  Engrailed-2 is down-regulated but also ectopically expressed in clear cell renal cell carcinoma.

Authors:  Cai-yong Lai; Bin Pan; Yun Luo; Wei-bo Liang; Jie Chen; Dong-ming Ye; Ji-Nan Guo; Li Li; Ze-xuan Su
Journal:  Mol Biol Rep       Date:  2014-02-16       Impact factor: 2.316

Review 7.  Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer.

Authors:  Carmine D'Aniello; Massimiliano Berretta; Carla Cavaliere; Sabrina Rossetti; Bianca Arianna Facchini; Gelsomina Iovane; Giovanna Mollo; Mariagrazia Capasso; Chiara Della Pepa; Laura Pesce; Davide D'Errico; Carlo Buonerba; Giuseppe Di Lorenzo; Salvatore Pisconti; Ferdinando De Vita; Gaetano Facchini
Journal:  Front Oncol       Date:  2019-12-11       Impact factor: 6.244

8.  Targeted therapies in the management of renal cell carcinoma: role of bevacizumab.

Authors:  Bernard Escudier; Jan Cosaert; Sangeeta Jethwa
Journal:  Biologics       Date:  2008-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.